Data suggest that FDG-PET tumor uptake may be used to predict how patients with bone sarcoma will respond to chemotherapy. All 65 patients with either bone sarcoma or soft-tissue sarcoma underwent PET imaging before doxorubicin-based neoadjuvant chemotherapy. Scans were collected again after two rounds of chemotherapy and ahead of surgery. Researchers found that tumor size, percentage change in SUVmax and tumor type had predictive value for patient survival, according to the study in The Journal of Bone & Joint Surgery.
Published in Brief: